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Abstract
Background: Pain is a very common condition in patient undergoing rehabilitation for neurological disease;
however the presence of primary headaches and other cranio-facial pains, particularly when they are actually or
apparently independent from the disability for which patient is undergoing rehabilitation, is often neglected.
Diagnostic and therapeutic international and national guidelines, as well as tools for the subjective measure of head
pain are available and should also be applied in the neurorehabilitation setting. This calls for searching the
presence of head pain, independently from the rehabilitation needs, since pain, either episodic or chronic, interferes
with patient performance by affecting physical and emotional status. Pain may also interfere with sleep and
therefore hamper recovery.
Methods: In our role of task force of the Italian Consensus Conference on Pain in Neurorehabilitation (ICCPN), we
have elaborated specific recommendations for diagnosing and treating head pains in patients undergoing
rehabilitation for neurological diseases.
Results and Conclusion: In this narrative review, we describe the available literature that has been evaluated in
order to define the recommendations and outline the needs of epidemiological studies concerning headache and
other cranio-facial pain in neurorehabilitation.
Keywords: neurorehabilitation patients, primary headaches, cranio-facial pain, non-pharmacological treatment,
psychological therapy, manual therapy, invasive treatment, ICCPN
Introduction
This narrative review is part of the activities of the
Italian Consensus Conference on Pain in Neurorehabil-
itation (ICCPN), an initiative of the Italian Society of
Neurorehabilitation – whose members are neurologists,
physiatrists, physical therapists and psychologists with a
specific and strong background in rehabilitation of
neurological disorders - aimed at performing a critical
appraisal of the scientific evidence on the role and the
consideration of pain in the rehabilitation of neuro-
logical diseases (www.sirn.net). The presence of pain,
independently from the rehabilitation needs, deserves at-
tention since pain, either episodic or chronic, interferes
with patient performance by affecting physical and emo-
tional status. Pain may also interfere with sleep and
therefore hamper recovery. Full details of the rationale
and the methodology of the ICCPN can be found in a
previous publication by Tamburin et al. [1]. The recom-
mendations of our working group on headache and
other cranio-facial pains (CFPs) have been recently pub-
lished in a short report [2]. Here we describe in a narra-
tive form the extensive work of data search and data
analysis performed to formulate the recommendations.
In order to comply with the aims and scope of a multi-
disciplinary approach to primary headaches (PHs) and
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other CFP in patients undergoing rehabilitation for
neurological diseases, the initial team, originally com-
posed by two neurologists with a long-term expertise in
headache management and neurorehabilitation (CT and
MGB) has been enlarged to include other health profes-
sionals: a neurologist with a specific background in pain
management (RC), two anaesthesiologists (VS and SB), a
psychologist (MD) and three physical therapists MT, VP
and RR. A further neurologist (MB) was added with the
key role of reference management.
As working tool for defining the search topics, we fo-
cused on 6 questions that were formulated by the Board
of ICCPN with the primary aim of identifying and sum-
marizing acquired evidence. A secondary important aim
was to highlight gaps and critical areas in order to foster
future targeted research.
The 6 questions elaborated by the Board of ICCPN are:
1) Do standard methods or criteria exist to evaluate
head and cranio-facial pain?
2) What is the specific impact of cephalic and cranio-
facial pain in neurorehabilitation?
3) What are the main types of cephalic and cranio-
facial pains?
4) Do predictive factors exist to develop cephalic and
cranio-facial pain?
5) What is the evidence for using pharmacological and
non-pharmacological therapies to treat cephalic and
cranio-facial pain?
6) What is the possible impact of treating cephalic and
cranio-facial pain on the recovery and neurorehabil-
itation treatment?
According to ICCPN methodology [1], we searched
the main databases for medical literature: Pubmed,
Medline, Embase, Scopus and the Cochrane Library.
The time period considered was 1984-2017. This time
period corresponded to the recommendations of the
task force of the ICCP [1] and was ratified by the Au-
thors of the present review based on the results of a
preliminary explorative search extended to the previous
decade (1974-1983), which did not yield any reliable tri-
als on the use of non-pharmacological treatment in
headache and on the consideration that the first
evidence-based structured classification of headache
disorders was published in 1988. Our review is pre-
sented in the form of review is a narrative review, A
more capillary search to comply with the criteria of a
systematic review was not warranted due to the wide
range of topics under evaluation in a single manuscript.
For sake of clarity, the keywords used for each question
and for each pain disorder are indicated in the corre-
sponding paragraphs. In the initial search, we included
all types of peer-reviewed evidence in English language:
case-control studies, cohort studies, RCTs, guidelines
(GLs), meta-analyses (MAs), systematic reviews (SRs),
case reports and expert’s opinion. These two latter
types of publication were excluded whenever there was
enough evidence from RCTs, GLs, SRs or MAs to an-
swer one or more questions. Reliable GLs were used as
very high-level reference. In the other cases, we also
considered case reports and experts’ opinions.
Background and Methods
Among pain syndromes, headaches and other CFPs, ei-
ther primary or secondary to local or systemic diseases,
represent an extremely frequent complaint. The Inter-
national Headache Society, in 2004, provided a thorough
revision of guidelines for proper diagnosis of any head
pain by defining, particularly for PHs, clinical character-
istics, presentation and recurrence over time (ICHD-II,
2004) [3]. The paucity of standard instrumental pain
measure tools enhances the value of individual percep-
tion of pain experience, while missing any objective
criterion. The ICHD-II, as well as its latest revision
(ICHD-IIIbeta, 2013) [4], are subdivided into three main
chapters: 1. Primary headaches; 2. Secondary Headaches;
3. Cranial Neuralgias, Central and Primary Facial Pain
and Other Headaches. While for PHs, the guidelines
propose qualification criteria of pain, for secondary head
pains, the international classification does not provide,
in most of diagnoses, pain characteristics, whereas it
makes mandatory the relationship between organic or
systemic conditions possibly responsible for pain. An ex-
ception is neuralgic pain, given its typical characteristics.
It is intuitive that in the presence of organic or systemic
diseases that can cause head pain, the observation tends
to answer to the yes/not parameter regarding the rela-
tionship between the symptom and the possible cause,
therefore moving the attention on the potentially remov-
able or treatable cause of pain rather than on symptom
characteristics. A peculiar condition is represented by
post-traumatic headache (PTH) [5], more frequently as-
sociated to minor head injuries rather than moderate,
severe or very severe ones. Up to 90% of subjects with
head trauma suffer from PTH, which can persist, at least
in a subset of them, for more than 3 months post injury,
thus qualifying as chronic PTH, a condition that dramat-
ically affects quality of life and function [6–8]. The
mechanism of chronic PTH is currently unknown, and
may involve peripheral or central changes, e.g. damage
to neck/cranial structures, damage to spinothalamic/
thalamocortical pathways, damage/dysfunction of pain
inhibition pathways and the frequent association of
post-traumatic stress disorder with anxiety, depression
and pain catastrophizing [9]. In the case of severe head
injuries, other specific factors such as bone fractures,
intra- or extra-cerebral haemorrhage, neurosurgical
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procedures, ventricular dilatation or hydrocephalus are
possible sources of pain (ICHD-II, 2004, ICHD-III,
2013) [3, 4]. Minor brain injury sequelae do not usually
enter the long-term neurorehabilitation processes and
are observed in neurology, psychology or as part of liti-
gation procedures. Most frequently, PTHs are described
with characteristics that resemble those of PHs, and di-
agnosed accordingly. This pitfall does not solve the
question regarding the specific features of PTH, nor
their underlying pathophysiology [5, 10]. Regaining of
cognitive functioning in patients with brain injury
seems to predict the reappearance of a pre-existing PH,
and namely migraine [11].
Results
In the following paragraphs, we summarize our findings
as regards questions n. 1, 3 and 5.
1) Do standard methods or criteria exist to evaluate
head and cranio-facial pain?
3) What are the main types of cephalic and cranio-
facial pains?
5) What is the evidence for using pharmacological and
non-pharmacological therapies to treat cephalic and
cranio-facial pain?
In the case of questions n. 2, 4 and 6, we could not
find any evidence, and this prevented to draw any
evidence-based conclusions or recommendations.
Namely, there are no data regarding the impact of PHs
and other CFP in patients undergoing rehabilitation for
neurological diseases and consequently no data regard-
ing the impact of their treatment in rehabilitation out-
come (questions 2 and 6). Concerning question 4, it
refers to the neurological diseases undergoing neuror-
ehabilitation and the intrinsic factors of these neuro-
logical diseases that may favour the development of
primary headaches and other CFP in neurorehabilita-
tion patients. An example of intrinsic factors of other
conditions that are capable of interfere with migraine is
represented by altered menstrual cycle in young women
after severe brain injury following trauma or haemor-
rhage. Another example is represented by cranio-spinal
traumas that may worsen tension type headache with
peri-cranial muscle tenderness or contraction. Besides,
data should be obtained regarding drugs that are com-
monly used in neurorehabilitation and their potential
impact on PHs or CFPs. This is the case for dantrolene,
baclofen and botulin toxin, used for reducing spasticity
in several neurological diseases, or for antiepileptic
drugs or drugs for the treatment of neuropathic pain in
trauma, multiple sclerosis and stroke. Unfortunately,
we could find any evidence as regards the predictive
factors to cephalic and cranio-facial pain in subjects
undergoing rehabilitation for other neurological condi-
tions, with the exception that regaining of cognitive
functioning in patients with severe brain injury seems
to predict the reappearance of a pre-existing PH, and
namely migraine [11].
The association of secondary cephalic pain syndromes
with neurological diseases undergoing rehabilitation rep-
resented the object of study from other ICCPN groups.
Q1 – Do standard methods or criteria exist to
evaluate head and cranio-facial pain?
The query finds its natural answer in the common use
of standard scales to evaluate pain intensity, namely the
visual analogue scale (VAS) [12]. Along with this, and
limited to migraine, the Migraine Disability Assessment
Score (MIDAS) is a useful tool. MIDAS is a very simple
questionnaire for patients to quantify the degree of dis-
ability due to migraine [13]. The Headache Impact Test
(HIT-6) is also recommended for capturing migraine-
related disability, but its use is subject to license [14].
The clinical usefulness of MIDAS and HIT-6 is however
limited by the lack of questions related to other condi-
tions, such as anxiety and mood disorders, that should
be mandatory in the presence of pain. When using the
monthly headache diary, usually patients are taught to
score their pain on a 0 to 3 scale (0 = no pain, 1 = mild,
2 = moderate, 3 = severe). Along with pain intensity, the
diary allows recording of headache frequency and dur-
ation (in hours), the presence of premonitory and/or ac-
companying symptoms to pain, as well as analgesic
intake and efficacy (the latter being measurable accord-
ing to pain relief or cessation after drug intake). This in-
strument allows to evaluate the efficacy of preventive
medications on the long term, through changes in fre-
quency, duration and severity of headache attacks over
time. The “diary” therefore emerges not only, or not spe-
cifically, as a tool for measuring pain, but more broadly
as an instrument to measure the disability related to
pain [15–17]. Several other instruments are available
from the literature for the evaluation of other dimen-
sions of headache-associated burden, but they do not
evaluate specifically pain, therefore we resolved to con-
sider them beyond the scope of this review. An extensive
list and associated evaluation is freely accessible via the
website of National Institute of Neurological Disorders
and Stroke (https://www.commondataelements.ninds.-
nih.gov/Headache.aspx#tab=Data_Standards).
Q3 – What are the main types of cephalic and
cranio-facial pains?
To answer this specific query, the work group discussed
and agreed on the appropriateness to refer to the diag-
nostic guidelines provided by the International Headache
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Society (ICHD-II and ICHD-IIIbeta) [3, 4]. These guide-
lines represent the universal diagnostic tool through
which any head or facial pain, either primary or second-
ary, can be diagnosed following a common language and
homogeneous criteria. In the absence of specific data
from the literature on the frequency of observation of
head pain in the neurorehabilitative setting, it seems rea-
sonable to estimate that the most frequent types of head
pain likely to be encountered in the neurorehabilitative
setting are tension-type headache and migraine, based
on their high prevalence in the general population. PTH
can be an acute or chronic sequela in post-traumatic pa-
tients. The most frequent non-neuropathic pain is Tem-
poromandibular Disorder (TMD), whereas Trigeminal
Neuralgia (TN) is the most frequent neuropathic one.
Local traumatic injuries (among which tooth extraction
are not infrequent) may contribute to local neuropathic
pain. Like these conditions, other pain syndromes, such
as Burning Mouth Syndrome (BMS) of which little is
known [18], require adequate instrumental diagnostic
procedures to individuate any possible cause and pos-
sible treatment. As suggested by Zakrzewska [19], in a
recent review on facial pains, the approach to patients
changes according to the first medical referral and man-
agement changes as well depending on the current spe-
cialist. This apparently useless comment implies that the
approach to pain should be on a multidisciplinary basis
to ensure adequate management.
Q5 – What is the evidence for using
pharmacological and non-pharmacological
therapies to treat cephalic and cranio-facial pain?
Pharmacological and non-pharmacological guidelines for
PHs are available by the Italian Society for the Study of
Headaches (Società Italiana per lo Studio delle Cefalee,
SISC) [20]. These guidelines refer to both pharmaco-
logical and non-pharmacological treatment for PH types.
We chose to refer to the Italian guidelines since the
ICCPN is nationally based. However, they were inte-
grated with a search of literature published after their re-
lease, which did not yield further significant information
regarding conventional pharmacological therapies. Given
the lesser strong evidence for non-pharmacological
treatments, a detailed description of the search results is
described in the following sections, as summarized in
Table 1. Particular emphasis was put on manual therapy
and psychological treatment, given their availability in
the neurorehabilitative setting, to endorse their use in
pain treatment even in those attendant conditions unre-
lated to the primary disability undergoing rehabilitation.
Manual therapy for PHs
An electronic search was done on Medline (Pubmed),
Embase and Cochrane Central Register of Controlled
Trials and Scopus. The reference lists of potentially rele-
vant trials, meta-analyses and systematic reviews were
also searched. The key words and phrases used were mi-
graine, tension-type headache, chronic migraine, chronic
daily headache combined with manual therapy, physical
therapy or physiotherapy, massage therapy, osteopathic
and chiropractic. All RCTs conducted on PHs written in
English using manual therapy (MT) were evaluated.
In order to answer the question, the task force, and
namely the physical therapists, reviewed all clinical trials
and reviews aimed to assess the effects of MT in patients
with PHs. Twenty-nine scientific articles were screened
for inclusion; 8 of them were excluded because manual
treatments were variously combined with nutraceutical
treatment, multidisciplinary approach, mental imagery
and kinesiotaping; 21 full-articles were reviewed.
For MT, we considered any physical treatment used by
physiotherapists, chiropractors, osteopaths, physicians to
treat and to manage musculoskeletal disorders and pain.
MTs include, but are not limited to, massage, dry need-
ling, soft tissue mobilization, instrument-assisted soft tis-
sue mobilization, rolfing, non-thrust manipulation
(mobilization), thrust manipulation (HVLA), myofascial
release, strain-counterstrain, muscle energy techniques
(MET) spinal manipulation (SM) and osteopathic manipu-
lative treatment (OMT). These manual interventions do
not use drugs for the treatment of pain syndromes and/or
diseases. Table 2 summarizes levels of evidence and grades
of recommendations of MTs for PHs.
Chiropractic therapy
A randomized, placebo-controlled, factorial clinical trial
of chiropractic and medical therapies in primary care
showed that the association of chiropractic treatment
(high velocity, low amplitude thrusting manipulation to
any dysfunctional joints from occiput to third thoracic
vertebrae) with amitriptyline is more effective than each
treatment administered individually, in patients with
chronic tension-type headache (TTH) [21].
Posadzki and Emst [22] evaluated the effects of SM in
patients with migraine: 3 RCTs were published before
Table 1 Treatments for PHs and other CFP as outlined in the text
Manual therapy
Psychological treatments
Innovative non-pharmacological interventions – Information and
communication technologies
Herbal extracts
Acupuncture
Local treatment
Botulinum toxin
Invasive treatment for chronic orofacial pain
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ICHD-II release, one of them [23] showed that the effect
of SM for the treatment of migraine is comparable to
placebo, the other two, showed no difference between
medication therapy and cervical manipulation [24] and
between medication therapy and SM [25] in terms of
Headache Index Score and headache duration. In the
same year, the Authors [26] published another system-
atic review to clear up the confusion about the use of
SM, concluding that there is no clear evidence of effi-
cacy for SM and emphasized the low quality of the stud-
ies included in the revision.
In 2012, the same Authors [27] reported results from
4 RCTs regarding SM for TTHs. Four RCTs, included in
the review, suggested that SM was more effective than
drug therapy, SM plus placebo, sham plus amitriptyline
or sham plus placebo, usual care or no intervention. It is
worth mentioning the paper by Chaibi et al. [28] where
the Authors propose a protocol design to solve the issue
regarding sham intervention to be used as placebo treat-
ment in clinical trials involving SM. A recent three-
armed, single-blinded, placebo, randomized controlled
trial [29], suggested that the effect of SM in migraine
patients is probably due to a placebo effect.
Osteopathic manipulative treatment
A RCT by Voigt et al. [30] analysed the effect of osteo-
pathic manipulative treatment (OMT) in female
migraine patients and highlighted the statistically signifi-
cant reduction of pain intensity and pain-related disabil-
ity in treated vs untreated patients. Cerritelli et al. [31]
comparing OMT to drug and sham groups, suggested
that OMT is a useful procedure for migraine
management. Recently, D’Ippolito et al. reported that
after four 45-min OMT sessions patients with high-
frequency migraine and comorbid mood disorders
showed significant improvement on pain and anxiety
disorders [32]. OMT may be preferred over other treat-
ment modalities and may benefit patients with adverse
effects to medications or difficulty in complying with
pharmacological treatments [33]. In a systematic review,
Cerritelli et al. [34] concluded that the evidence support-
ing the effectiveness of OMT in decreasing pain inten-
sity and frequency, as well as in reducing disability in
patients with headache, is still preliminary and methodo-
logically poor.
Myofascial release technique
The myofascial release technique proved more effective
than the control treatment (simple touch) in patients
with episodic and chronic TTH [35]. The efficacy of
combination of myofascial muscular and manipulative
techniques has been reported for pain-related disability
and pericranial tenderness in TTH [36] as well as for
pain perception and neck mobility [37]. For both epi-
sodic and chronic TTH, joint mobilization, muscle
stretching, soft, connective and muscle tissue manipula-
tion were more effective in the short and long period
when compared to conventional treatments [38, 39].
Multimodal approach
A SR published in 2011 [40] has evaluated the effects of
different types of MT (intended as combination of differ-
ent modalities) in patients with migraine. Seven trials
were reviewed, including 6 studies published before
Table 2 - Summary table of levels of evidence [181] and grades of recommendations of manual therapies for primary headaches
Type of manual therapies Levels of evidence Grades of recommendations
Chiropractic therapy 1- C
Osteopathic Manipulative Treatment 1+ B
Myofascial technique 2- D
Multimodal Approach 2- D
Legend for Levels of evidence
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+ Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews, or RCTs with a high risk of bias
2++ High quality systematic reviews of case control or cohort or studies; high quality case control or cohort studies with a very low risk of confounding or bias
and a high probability that the relationship is causal
2+ Well-conducted case control or cohort studies with a low risk of confounding or bias and a moderate probability that the relationship is causal
2- Case control or cohort studies with a high risk of confounding or bias and a significant risk that the relationship is not causal
3 Non-analytic studies, e.g., case reports, case series
4 Expert opinion
Legend for Grades of recommendations
A: At least one meta-analysis, systematic review, or RCT rated as 1++, and directly applicable to the target population; or a body of evidence consisting principally
of studies rated as 1+, directly applicable to the target population, and demonstrating overall consistency of results
B: A body of evidence including studies rated as 2++, directly applicable to the target population, and demonstrating overall consistency of results; or
extrapolated evidence from studies rated as1++ or 1 +
C: A body of evidence including studies rated as 2+, directly applicable to the target population and demonstrating overall consistency of results; or extrapolated
evidence from studies rated as 2++
D: evidence level 3or4; or extrapolated evidence from studies rated as 2 +
GPP: recommended best practice based on the clinical experience of the guideline development group
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ICHD-II [3] release. The results suggest that physiother-
apy (massage, muscle relaxation, breathing exercise and
thermal bio-feedback) and SM can be equally useful in
migraine prophylaxis as propranolol or topiramate, but
the methodological quality of the studies included is
low, and only four studies showed statistically significant
reductions.
A SR [41] assessing the quality of RCTs published
from the year 2000 to April 2013 reports that the effect-
iveness of MT for TTH cannot be completely assessed
due to the heterogeneity in study design, outcome mea-
sures, and different treatments. Nevertheless, the results
suggested that patients with TTH receiving MT (spinal
mobilisation, SM, acupressure and OMT) showed better
progress than those receiving conventional treatment or
placebo. A further SR [42] evaluated the efficacy of MT
(massage, mobilization of cervical and thoracic spine, re-
laxation and stretching) in chronic PHs, showing that
MT has an efficacy in the management of chronic TTH
that equals preventive medication with tricyclic antide-
pressants. A SR and MA [43] conducted to evaluate the
effectiveness of interventions used by physiotherapists
(relaxation, posture correction, exercises, education for
muscle tension release, resistance training, orofacial
techniques and mobilization) on patient with migraine
and TTH showed statistically significant reduction in
the intensity, frequency and duration of headache. The
Authors concluded suggesting the need of methodo-
logical adequate RCTs. Fernández-de-Las-Peñas and
Cuadrado [44] state that several types of MT (joint ma-
nipulation and/or mobilization, soft tissue interventions,
therapeutic exercises and needling therapies) used in a
multimodal approach could be effective for headache
management.
In summary, studies related to MT do not allow con-
clusive indications in PHs, although there is some com-
pelling evidence on the efficacy of MT in episodic and
chronic TTH. Further studies based upon rigorous
methodology are needed. More specifically, careful selec-
tion of homogeneous populations, precise evaluation of
frequency and duration of treatments (or their associ-
ation) and comparable methods to assess outcome
reliability are needed.
Manual therapy for other cranio-facial pains
We conducted a search on Medline (Pubmed), Embase
and Cochrane Central Register of Controlled Trials and
Scopus. The reference lists of potentially relevant trials,
meta-analyses and systematic reviews were also searched.
The key words and phrases used were orofacial pain, tem-
poromandibular disorders, orthodontic treatment, manual
therapy, massage therapy, physical therapy. In the initial
search, ninety-eight full papers identified through database
searching, twenty-one papers were screened for inclusion
and twelve full-articles were reviewed.
Cranio-facial pain (CFP) may be a manifestation of dif-
ferent diseases resulting from periodontal, vascular or
sinus bone alterations, cancer or temporomandibular joint
disorders (TMJDs) [45]. Cervicogenic headache (CGH), a
secondary headache due to neck disorders (Code 11.2.1 in
the ICHD-III) [4], is often treated with MT, but pain
reduction and frequency reduction do not reach clinically
relevant effect [43]. Treatments for TMJ disorders can be
non-invasive, invasive and partially invasive [46]. Among
the non-invasive non-pharmacological therapies the avail-
able choices are occlusal splints, physical therapy, MT
and acupuncture. The scientific literature highlights a
lack of strong evidence on the effectiveness of ortho-
dontic treatment to treat and prevent TMDs, including
occlusal splints that do not significantly reduce the pain
[47, 48]. The RCT by von Piekartz and Hall [49] carried
out on patients with CGH associated to TMJD, showed
that the group that received MT to treat TMJD, in
addition to cervical MT, showed significant reduction
(that persisted to the 6-month follow-up) in all compo-
nents of cervical impairment. The same was not ob-
served in the cervical MT-treated group at any point.
These observations indicate that manual therapists
should look for features of TMJD when examining pa-
tients with cervical disorder, particularly if treatment
fails when directed only to the latter [50].
Another RCT [51] reports clinical short-term benefit,
yet not statistically significant, on pain intensity and
joint range with MT and home exercise program.
Although Moraes et al. [52] suggest that certain thera-
peutic exercises can be effective, studies performed to
verify the effects of MT used as combination of conser-
vative treatments prevent any attribution of effects to a
specific treatment. Overall, systematic reviews show the
poor quality of studies and lack of strong evidence for
elaborating reliable recommendations. In the absence of
evidence-based recommendations, conservative treat-
ment reasonably represents the first choice for any pa-
tient. Surgical treatments should be considered only
after failure of conservative approaches and should not
be proposed in asymptomatic or lightly symptomatic
patients [53–56].
Psychological treatments in PHs
The key words used in the literature search were psy-
chological interventions, cognitive-behavioural therapy,
relaxation training, biofeedback, EMDR, mindfulness
therapy, hypnosis combined with headache, migraine,
tension-type headache and chronic headache. A total of
80 publications were found. The final analysis was
conducted on 23 studies.
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Psychological treatment is useful to prevent headache
progression to chronic form but it should be considered
as an integration to pharmacological treatments, rather
than an alternative tool. Psychological treatment is also
an important part of headache therapy, since it can be
used to manage the mood disorders often comorbid in
patients with migraine. In fact, many studies suggested
that migraine patients are usually comorbid to depres-
sion and anxiety [57, 58] which are recognized to influ-
ence the prognosis and treatment, being a major risk
factor associated with poorer outcome [59, 60].
The comorbidity with major affective disorders is
more prevalent in subjects suffering from the chronic
type of migraine [61], who frequently report high levels
of hopelessness and show a higher suicidal risk [62].
This consideration underscores the usefulness of an ap-
propriate psychological assessment of migraine subjects
and the opportunity to associate specific treatment in
the subjects with psychiatric comorbidity. Table 3 sum-
marizes levels of evidence and grades of recommenda-
tions of psychological treatments for PHs.
Cognitive-Behavioral Therapy (CBT)
CBT, the most common and successful psychological ap-
proach in treating pain, is effective in reducing disability
and catastrophic reaction, whereas the effects on pain
intensity are negligible [63]. CBT assesses dysfunctional
emotions and thoughts and maladaptive behaviours aim-
ing to reduce the emotional and physical suffering asso-
ciated with pain and to mitigate psychological disorders
[64], such as anxiety and mood disorders. Although it is
rare for patients to become pain free, CBT helps to re-
duce pain, by keeping it under control [65]. Patients
learn how to manage and therefore to reduce disability
and related psychic-emotional worry [66, 67]. Positive
outcomes have been detected also in patients with
chronic daily headache (with or without medication
overuse), when treated with CBT alone or in association
with pharmacological treatments [68]. Penzien and coll.
[69] found that CBT reduces disability in TTH by 50%,
compared to the 33% reduction observed following
treatment with amitriptyline. A qualitative study con-
ducted by Morgan et al. [70] on 20 adult migraine pa-
tients with at least four headache days per month,
reported that CBT was identified by patients as a good
‘tool’ in preventing and managing their attacks and redu-
cing stress. In addition, Gunreben-Stempfle and coll.
[71] demonstrated that behavioural management of mi-
graine increases the belief that migraine can be influ-
enced by one’s own behaviour and decreases the belief
that migraine is primarily influenced by chance or fate.
Systematic reviews [72, 73] stated that the potential ef-
fectiveness of CBT in headaches is still unknown, even
though it may contribute in the long run to avoid side-
effects and costs of medications, as well as other associ-
ated health service and personal costs [74].
Mindfulness Therapy (Mind-T) and Acceptance and
Commitment Therapy (ACT)
During the last two decades, new clinical interventions,
i.e. Mindfulness Therapy (Mind-T) and Acceptance and
Commitment Therapy (ACT) (third-generation behav-
ioural therapy), have been developed. Mind-T based in-
terventions [75] include meditation and yoga, and focus
on the importance of being fully engaged in the present
rather than worrying about past or future events. Grant
[76] pointed out that meditative practices may positively
influence the underlying processes of chronic pain, thus
emphasizing their high pain-killer function. A RCT by
Cathcart e coll. [77] reported the efficacy of
Mindfulness-Based Cognitive Therapy (MBCT) in the
treatment of chronic TTH, while Wells e coll. [78],
through a pilot study on 19 migraine patients undergo-
ing Mindfulness-Based Stress Reduction (MBSR), re-
ported positive effects on migraine attack duration and
related disability, although they failed to demonstrate
statistically significant changes in attack frequency and
intensity. ACT points to the development of psycho-
logical flexibility, the ability to experience the present
moment and accept negative thoughts without judge-
ment. Mo’tamedi et coll. [79] showed ACT efficacy in
reducing headache disability and its related distress, but
not in decreasing the sensory perception of pain in 30
patients suffering from either chronic TTH or migraine
without aura. The paucity and limitation of available
studies suggest the need to extensively assess ACT be-
fore recommending it for the treatment of chronic pain
[80], however both ACT and Mind-T show considerable
promise for improving outcomes of migraine patients,
particularly in reducing headache-related disability and
affective distress.
Table 3 Summary table of levels of evidence [181] and grades
of recommendations of psychological treatments for primary
headaches
Type of psychological
treatments
Levels of
evidence
Grades of
recommendations
Cognitive-behavioral therapy 1+ A
Acceptance and Commitment
Therapy
1+ A
Mindfulness Therapy 4 GPP
Relaxation training 2++ B
Biofeedback 1+ A
Eye Movement Desensitization
and Reprocessing
2+ C
Hypnosis 2+ C
Legend Levels of evidence and Legend Grades of recommendations as for
Table 2
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Relaxation training (RT)
Relaxation training (RT) is a behavioural technique
which helps to break the cycle of stress response favour-
ing physiological and psychological relaxation, which will
then facilitate rational and logical thought processes
[81]. RT includes progressive muscle relaxation, breath-
ing exercises, autogenic training, guided imagery, medi-
tation and audio-video programs, commonly used as
facilitators [82]. RT mitigates sympathetic nervous sys-
tem excitement and muscle tension to ease body relax-
ation in order to manage anxiety that can cause
headache recurrence [83–85].
Aerobic endurance training (AET) can be also recom-
mended as part of multidisciplinary programs for mi-
graine treatment [86–89], since it has been revealed that
it may lead to an increased pain threshold and reduce
the migraine attacks frequency, by improving the atten-
tional performance of patients [90]. AET is considered
an encouraging alternative for migraine patients, even
though high-quality studies are scant [89].
Biofeedback (BFB)
Biofeedback (BFB) training has been proven to mitigate
migraine, increase RT efficacy and manage pain and
stress [91–94]. Patients learn to modulate muscle ten-
sion, peripheral body temperature, heart rate, by means
of self-control and relaxation techniques, in order to re-
duce or eliminate headache symptoms [95]. In particular,
electromyographic (EMG), thermal, and electrogalvanic
BFB interventions are effective in patients involved in
multidimensional programs, in addition to CBT, or ad-
ministered as single treatment [96]. The US Headache
Consortium [97] assigned the highest level of evidence
to thermal and EMG-BFB in migraine treatment and
stress management, and the meta-analysis conducted by
Nestoriuc et al. [98] stated that BFB interventions can be
effective for the treatment of TTH and migraine. Ac-
cording to Lake [99], behavioural treatments, such as
BFB training and relaxation therapy, may have a prophy-
lactic efficacy in migraine.
Eye Movement Desensitization and Reprocessing
Eye Movement Desensitization and Reprocessing
(EMDR), aiming at reducing the long-lasting effects of
distressing memories by developing more adaptive cop-
ing mechanisms [100], may be effective in the treatment
of chronic pain. An observational clinical trial using a
pre-test/post-test design with a 3-month follow-up [101]
investigated the efficacy of EMDR in migraine patients
by specifically treating traumas related to headaches
(e.g., first experienced/remembered headache attack and
recalled traumatic events associated to the first headache
attack). Patients received an average of eight 50-min
sessions on a weekly basis over a 3-month period. At the
3-month follow-up, significant decreases in headache
frequency and duration occurred, with less analgesic
intake, but no reduction in pain intensity.
Hypnosis
Hypnosis may be used on adult patients with migraine
and headache [102–104] and it is advised for patients
with Persistent Idiopathic Facial Pain [105] or temporo-
mandibular disorders (TMDs) [106, 107].
Psychological treatments for other CFPs
The key words used in the literature search were psy-
chological interventions, cognitive-behavioural therapy,
relaxation training, biofeedback, EMDR, mindfulness
therapy, hypnosis combined with facial pain, facial neur-
algia, trigeminal neuralgia and temporomandibular
disorders.
TMDs are major causes of non-dental pain in the oro-
facial region, and may also induce headache [108]. The
International Classification of Headache Disorders, 3rd
edition (ICHD-3) [4] recognizes headache attributed to
TMDs and identifies specific criteria but, since headache
and TMDs are very frequent, have multifactorial origins,
and have similar or overlapping symptoms, diagnosis is
often confused. A key component in the management of
patients with TMDs is the behavioural modification of
maladaptive habits [109]. A review by Aggarwal and coll.
[110] underlined that CBT, either alone or in combin-
ation with BFB, can improve outcomes for patients with
TMDs in secondary care. However, further research is
needed to assess its efficacy in primary care and in man-
agement of other chronic orofacial pain conditions
[111]. The emphasis is on a medical multidisciplinary
model similar to those used for other musculoskeletal
disorders [112]. It is also important to tailor treatment
to individual patient needs and preferences [113].
Patient education is a significant part of pain therapy,
since it can improve the adherence to non-
pharmacological therapy by increasing self-efficacy and
influencing the locus of control. By improving know-
ledge of their headache disorder, patients may be more
successful in managing their disease, being active in the
therapy [114]. It is conceivable that patient education, as
part of multidisciplinary treatment, may contribute to
improve chronic pain syndromes [114].
Innovative non-pharmacological interventions –
Information and communication technologies (ICT)
Among the more innovative non-pharmacological
approaches to headaches, it is noteworthy mentioning
the international project coordinated by the National
Neurological Institute “C.Mondino” (Pavia, Italy)
(funded by the European Commission), which proposes
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the adoption of a headache diary supported by alerts and
alarms for the patients and the doctors (www.comeos-
tas-project.eu) as an adjunct tool for the management of
medication overuse headache (MOH). A said above,
patients suffering from headache are usually asked to
record their attacks. The diary results in a useful tool to
monitor pain and drug use/overuse, as well as to obtain
an improved control of relapses into overuse [115]. Very
little is known about the applicability of electronic diar-
ies in MOH patients, but their implementation seems
important also as mean for empowering the patients in
the self-management of their condition. Encouraging re-
sults have been reported by Sorbi and coll. [116] in a
pilot study conducted on 100 patients with chronic mi-
graine, which demonstrated the feasibility and accept-
ability of an online digital assistance (ODA), intended as
an adjuvant to face-to-face or Internet-based cognitive
behavioural treatment. ODA application was designed to
support home-based training of behavioural attack pre-
vention in chronic migraine, focusing on the identifica-
tion of attack precursors and the support of preventive
health behaviour. According to the Authors, ODA seems
to offer a generic tool to combine mobile coaching with
diary monitoring, independently of time and space. The
effectiveness of these ICT tools on headache improve-
ment remains to be established. Although several quali-
fied studies are published regarding internet-delivered
psychological therapies, there is insufficient evidence to
draw conclusions regarding this approach [117].
Herbal extracts
This topic has been subject to review for the implemen-
tation of the SISC guidelines [20], already mentioned, to
which reference should be made for PHs. More recent
studies seem to suggest a possible role of Chinese herbs,
but the description of active principle is lacking and the
quality of studies is low, especially for characterization
of patients and interventions [118, 119]. No scientific
evidence was found on other CFP and treatment with
herbal extracts.
Acupuncture
An electronic search was done on Medline (Pubmed),
Embase and Cochrane Central Register of Controlled
Trials and Scopus. The key words and phrases used were
facial pain, facial neuralgia, trigeminal neuralgia, head-
ache, migraine, TTH combined with acupuncture.
Acupuncture treatment seems effective up to 3 months
in TTH; efficacy on migraine attacks has been reported
but data are weak and as regards migraine prevention
data are still controversial. As stated in SISC guidelines
[20], the control (sham-acupuncture) utility and efficacy
has not been clarified yet. Acupuncture has been used to
treat other orofacial pain syndromes. In the controlled
study conducted by Simma et al. [120], acupuncture
showed an immediate effect higher than the sham treat-
ment. However, the limited number of patients and in-
adequacy of sham treatment do not allow conclusive
results although a systematic review highlights the
short-term utility of acupuncture (compared to sham
acupuncture) in muscle-originating facial pain [121]. It
is extremely difficult to quantify the real effectiveness of
active acupuncture treatment. As recently discussed, an-
other major issue is represented by the variability of
methodology (needle positioning, treatment duration,
session frequency), which contributes to outcome vari-
ability [122]. Both reviews by Yang et al. [123] and Linde
et al. [124] conclude that verum acupuncture may have a
higher effect than sham acupuncture over migraine re-
currence, but rigorous RCTs are needed. A recent trial
[125] concluded that acupuncture may be associated
with long-term reduction of migraine recurrence com-
pared to sham acupuncture. However, as stated by Gel-
fand [126], the placebo effect linked to the Deqi
sensation (numbness, soreness and distension induced
in acupuncture group, and not in sham group) may be
responsible for the apparent efficacy as placebo effect.
The issue remains, therefore, controversial.
Local treatment
An electronic search was done on Medline (Pubmed),
Embase and Cochrane Central Register of Controlled
Trials and Scopus. The keywords and phrases used were
topical treatments combined, topical lidocaine, topical
ketamine, topical amitriptyline, topical clonidine, topical
capsaicin combined with neurofacial pain, localized
neuropathic and chronic pain.
The possibility of topical administration of pain
killers has been developed nearly 20 years ago. Since
then, topical medications have been made available as
gel, cream, spray, mouthwash and even lollipop. The ef-
fects of capsaicin, lidocaine, gabapentin, clonazepam,
amethocaine delivered as topical therapies are well
known in orofacial pain syndromes. Local pharmaco-
logical therapies are available as topical or trans-dermal
preparations [127, 128]. Topical treatment is defined as
local application of substances that are absorbed locally
and have an effect confined to the site of application.
This is also the case of endo-oral application such as
lidocaine in dental procedures. Alternatively, trans-
dermal absorption provides local absorption and sys-
temic effects (other examples are nitrates or hormonal
or nicotine delivery). The drug, locally administered, is
intended to stimulate local receptors to reduce local
nociceptive “traffic”, thus inhibiting hyperactivity and
central sensitization. Mason et al. [129], after reviewing
16 meta-analyses, concluded that the reliability of cap-
saicin efficacy on neuropathic and muscle-skeletal pain
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is not guaranteed, even though the substance is more
effective than placebo. The evidence from controlled
trials on the efficacy and tolerability of topically ap-
plied, high-concentration (8%) capsaicin in chronic
neuropathic pain in adults is reported by Derry et al.
[130] who also report that the additional proportion of
subjects who benefit over control is not large, but for
those who do obtain high levels of pain relief there are
additional improvements in sleep, fatigue, depression
and quality of life. However, as Authors highlight, even
when efficacy is established, there are unknown risks
following repeated application on the long run, espe-
cially on epidermal innervation. Conversely, there are
insufficient data to draw any conclusions about the effi-
cacy of low-concentration capsaicin cream in the treat-
ment of neuropathic pain [131]. A retrospective study
shows that 8% capsaicin patch induces relief of pain up
to 12 weeks in patients with severe neuropathic pain.
The effect is fast, starting right after placement, it is
well tolerated, but it is cost-limited [132]. Cochrane Li-
brary reviews evaluated efficacy and tolerability of cap-
saicin and lidocaine in HIV-post-herpetic neuralgia,
peripheral neuropathies and osteoarthritis [133]. Capsa-
icin, either at low (0,075%) or high (8%) concentration,
is able to induce relief in chronic neuropathic pain in
adults with limited and transient side effects. Low dose-
capsaicin cream shows better efficacy compared to pla-
cebo, whereas high dose-capsaicin creams have higher
efficacy on pain as well as on pain-related symptoms,
such as sleep and life quality. High dose capsaicin patch
provides efficacy equal to other systemic therapies.
However, the high cost and the permanent disruption
of local peripheral sensory fibres should advise to limit
its use to those cases unresponsive to other therapies
and to avoid repeated local delivery in the absence of
severe pain. Topical lidocaine has a low impact on pain
and it cannot be recommended as local therapy for
neuropathic pain [134, 135]. Local treatment associated
with systemic drugs have been suggested for the BMS
[136–138]. A review [139] on this issue outlines the
efficacy of a combined treatment approach.
Botulinum toxin type A (BTX-A) for PHs
The key words used in the literature search were botu-
linum toxin combined with migraine, tension-type head-
ache, chronic migraine and chronic daily migraine. As
already reported in the SISC guidelines [20], as regards
to the primary episodic headaches, BTX-A has shown
good efficacy in several open-label studies while contra-
dictory results have emerged from double-blind-
controlled-placebo-studies. The studies carried out have
used different protocols, both individualized and
standardized, different sites of inoculation and dis-
homogeneous groups of patients (especially in terms of
attack frequency). A meta-analysis subsequent to SISC
guidelines [140] did not confirm the efficacy in episodic
PHs, at variance from what initially indicated by open-
label studies. Regarding chronic headaches, and as
already indicated by the SISC guidelines [20], the data
relating to BTX-A controlled-studies in chronic migraine
support its effectiveness on multiple indicators of head-
ache, disability and patient quality of life. This effect is
comparable to that of drugs of proven efficacy in chronic
migraine such as topiramate. The meta-analysis by
Jackson et al. [140] confirms the efficacy of BTX-A in
chronic daily headache and chronic migraine. The
randomized-placebo-controlled Phase III REsearch
Evaluating Migraine Prophylaxis Therapy (PREEMPT)
studies, extended to 56 weeks of observation, shows the
greater effectiveness of BTX-A compared with placebo
in chronic migraine, although there is not a direct com-
parison with other active drugs, and although the pla-
cebo effect is quite high [141, 142]. A subsequent
analysis of the PREEMPT data [143], aimed at evaluating
the effectiveness of BTX-A on subjects with chronic mi-
graine and acute medication overuse, showed that BTX-
A is more effective than placebo in reducing headache
days, but it does not significantly reduce the consump-
tion of overused symptomatic drugs, except for the trip-
tans. The retrospective study of Lin et al. [144] on the
efficacy of BTX-A in refractory chronic migraine has the
limitation to have included in the review subjects treated
with different protocols and with a follow-up certainly
shorter than the PREEMPT study mentioned above, and
therefore does not offer further evidence than those
already known. As outlined by Silberstein et al. [145],
similarly to other preventive drugs, repeated injections
(at least two or three) are recommended to evaluate re-
sponse to the treatment. The confirmation of the effi-
cacy of Onabotulinumtoxin A at the dose of 195 U in
Medication Overuse Headache came from the largest
post-marketing two years open-label prospective study
by Negro et al. [146].
Botulinum toxin type A (BTX-A) for other CFPs
An electronic search was done on Medline (Pubmed),
Embase and Cochrane Central Register of Controlled
Trials and Scopus. The key words and phrases used were
botulinum toxin combined with trigeminal neuralgia and
facial pain.
BTX-A has acquired a further field of application rep-
resented by trigeminal neuralgia (TN) refractory to drug
therapy for which reference is made to the guidelines of
the European Federation of Neurological Societies
(EFNS) [147]. The first open-label study, on the efficacy
of BTX-A in the treatment of TN was published in 2002
[148]. The Authors report a 50% reduction of pain and
frequency of attacks in 8 of 11 patients who were
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enrolled in the study and treated with 25-75 IU. These
results were later confirmed in equally limited numbers
of patients: 8 patients, in an open label study [149]; 13
patients, in another open-label study [150]. Zúñiga et al.
[151], confirmed in a further open-label study conducted
on 12 patients, the immediate disappearance of pain in
10 subjects, and the disappearance of the trigger zone
within 2 weeks of treatment with BTX-A, while Bohluli
et al. [152], in an open-label study on 15 patients,
showed that after BTX-A administration, 7 patients no
longer required any pharmacological treatment, 5 pa-
tients could successfully manage residual pain with non-
steroidal anti-inflammatory drugs (NSAIDs) and 3
subjects returned to be sensitive to pharmacological
therapy with anticonvulsants. The first randomized,
placebo-controlled, double-blind study was published in
2011 by Sirois [153]. In this study, the Author intro-
duced a parameter to quantify the effect id BTX-A: the
percentage of global pain relief which was considered
significant when higher than 50%. The Author concludes
that, limited to the number of patients assessed, BTX-A
may represent an effective treatment for TN. Those find-
ings were confirmed in a subsequent randomized,
placebo-controlled, double-blind study conducted on 42
patients [154]. In particular, the Authors report a signifi-
cant reduction of pain in the second week after injection
with BTX-A and a reduction in frequency already from
the first week; the effects were maintained throughout
the duration of the study (12 weeks). These data were
confirmed by Shehata et al. [155] in a similar experimen-
tal design on 20 patients. Cruccu and Truini [156] evalu-
ated the published studies and case reports and rated
the results as excellent: the percentage of response in 81
patients treated is 85%, a percentage comparable to that
achieved by pharmacological treatment with carbamaze-
pine/oxcarbamazepine, with a mean duration of effect-
iveness of 105 days. It must be however noted that
Verma [157] came to opposite conclusions as he rated
the scientific reports available at that time insufficient to
define effective BTX-A in the treatment of TN. A similar
opinion was also expressed by Hu et al. [158] who iden-
tified in the variability of the procedures and in the low
number of patients the greatest limitations preventing to
recommend BTX-A as a therapeutic option in NT. The
advantage of BTX-A, as compared to invasive ablative
methods is instead underlined by Guardiani et al. [159]
who encourage further randomized controlled trials.
Finally, an additional indication to the use of BTX-A is
represented by hemifacial spasm. The review by Costa et
al. [160] reports the results of large case-control studies
that show a rate of benefit between 76 and 100%. Des-
pite the scarcity of good quality data, all available studies
suggest that BTX-A is effective and safe for treatment of
hemifacial spasm.
Invasive treatment for chronic orofacial pain
An electronic search was done on Medline (Pubmed),
Embase and Cochrane Central Register of Controlled
Trials and Scopus. The keywords and phrases used were
facial pain, facial neuralgia, trigeminal neuralgia, glosso-
pharyngeal neuralgia, atypical facial pain and neuroabla-
tive therapy, microvascular decompression, surgical
therapy, invasive therapy or treatments, percutaneous
techniques, neurostimulation, neuromodulation, acu-
puncture, anaesthetic blocks, rehabilitation, physiother-
apy, physical therapy. Thirty-one adequate studies were
identified (5 meta-analysis, 4 RCTs, 6 prospective non-
randomized study, 2 reviews, 2 retrospective studies, 2
case series, 1 case report) and evaluated. Invasive proce-
dures in chronic facial pain are used when drug therap-
ies or other local non-ablative treatments have been
unsuccessful, poorly tolerated or not feasible because
contraindicated in the specific patient. Literature con-
cerning invasive procedures in chronic orofacial pain are
described according to specific diagnosis.
Trigeminal neuralgia
According to Gronseth et al., trigeminal neuralgia re-
fractory to pharmacological therapy may be treated
with neurosurgical procedures like microvascular de-
compression (MVD), Gasserian ganglion percutaneous
denervation’s or stereotactic radiosurgery (Gamma
Knife) [161]. There is very low-quality evidence for long
term pain relief of these procedures, while some
patients may experience transient or permanent sen-
sory deficits [162]. Regarding MVD, some data suggest
better efficacy compared to Gamma Knife or percutan-
eous techniques although no studies demonstrate a
longest pain relief [162, 163]. Pollock et al. reported
that MVD has the best cost/benefit ratio in the long
term and should be the first choice for patients who
can undergo general anaesthesia [164]. Gasserian gan-
glion percutaneous denervation’s like radiofrequency
rhizotomy (RFT), retrogasserian glycerol injection or
Gasserian balloon compression are employed in pa-
tients without evidence of neurovascular conflict or in
case of contraindication to MVD or general anaesthesia
but there are a lack of controlled clinical trials compar-
ing these three different techniques [165]. A prospect-
ive, non-randomized study shows that retrogasserian
glycerol injection and RFT can induce a moderate re-
duction in pain in refractory trigeminal neuralgia [166].
Finally, Gamma Knife radiosurgery may be considered
as first line approach in aged patients, in patients with
multiple sclerosis or in case of MVD inefficacy [167].
Glossopharyngeal neuralgia
The features of glossopharyngeal neuralgia pain are simi-
lar to those of TN. Pharmacological therapies for TN are
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frequently unsuccessful in glossopharyngeal neuralgia.
Invasive procedures are employed but data regarding
efficacy are lacking [168].
Temporomandibular joint disorder (TMJD)
Although the review by de Souza et al. [53] includes
three RCTs, it does not provide conclusive indications
about the local drug infiltration in the osteoarthritic
TMJD. A prospective randomized study comparing dif-
ferent combinations of arthrocentesis of the temporo-
mandibular joint associated with injection of low or high
molecular weight hyaluronic acid or cortisone demon-
strates the effectiveness of different treatments without
statistical difference between them [169].
Facial neuralgia (facial not trigeminal typical pain)
Two selected RCTs evaluating the block of the stellate
ganglion [170] and acupuncture in myofascial pain [171]
did not provide information on the evolution of chronic
facial pain. The study by Salvaggio et al. [172], with a
long-term follow-up after stellate ganglion block sug-
gests the usefulness to use it in the early treatment.
There are no clinical studies evaluating local anaesthesia
in facial neuralgia or facial pain. Published studies in-
clude a small sample or case reports.
Cluster headache
The greater occipital nerve (GON) block reduces attacks
in two thirds of patients with cluster headache [173].
The sub-occipital injection of long half-life steroids was
effective in two double-blind controlled studies [174].
Glycerol injection, radiofrequency rhizotomy, micro-
vascular decompression of the Gasserian or pterygopala-
tine ganglion and the superficial petrosal nerve block or
resection are ineffective for the prophylaxis of chronic
cluster headache (CCH) even in case of complete tri-
geminal denervation and may produce complications
like secondary trigeminal neuralgia and painful anaesthe-
sia. Gamma Knife radiosurgery showed no medium or
long-term effects in front of a high rate of complications
and failure of the technique and therefore is not recom-
mended for treatment of intractable CCH [175, 176].
According to Fontaine et al. [177] and Magis et al. [178],
occipital nerve stimulation (ONS) may act as a prophy-
lactic treatment in CCH. They suggest that, considering
their respective risks, ONS should be proposed before
deep brain stimulation in severe refractory CCH pa-
tients. The lower posterior hypothalamus stimulation
was effective in most patients with non-responsive clus-
ter headache [179, 180]. Sixteen RCTs have been pub-
lished on ONS or deep brain stimulation in CCH. All
these studies show effectiveness of the interventions but
with a poor level of evidence. Studies about radiother-
apy, sphenopalatine ganglion treatment (electro-
stimulation in acute headache, radiofrequency ablation
in chronic headache) [181, 182] and occipital injection
with steroids have a very low level of evidence (uncon-
trolled studies including small samples).
Discussion and conclusions
Before submitting the present review, a further check of
salient literature was done and no significant data were
found regarding assessment and treatment of PHs and
other CFP conditions in patients undergoing rehabilita-
tion for neurological diseases. Treatment of primary or
secondary headaches and facial pain is advocated in all
conditions and should be pursued also in neurorehabil-
itative settings in order to alleviate all conditions affect-
ing the patients’ quality of life and to improve their
compliance to rehabilitation treatments and outcome.
Furthermore, this is a major issue that has legal implica-
tions, following the publication of the national law ema-
nated by the Italian Ministry of Health, which requires
recording and treatment of any chronic pain in all hospi-
talized patients, regardless of the disease for which they
are under treatment (Gazzetta Ufficiale, 2010) [183]. The
lack of observational studies regarding the impact of
headaches and CFPs in neurorehabilitation and the im-
pact of their treatment on the rehabilitation outcome
does not allow to quantify the burden of these condi-
tions in rehabilitation patients. However, it is desirable
that PHs, which are more frequent in young and adult
subjects, should be sought and addressed at least in
these two populations when they happen to require re-
habilitation for other neurological conditions. The same
applies for all patients with rehabilitation demanding
conditions that are possibly responsible for secondary
headaches and CFP. This issue has been addressed by
other groups of the ICCPN. It is conceivable that ap-
proaching the pain component of the disease (as well as
co-existing PHs and other CFPs) in these patients, may
improve their psychophysical condition, favour adher-
ence to rehabilitation setting and therefore influence the
outcome as well as the quality of life. Furthermore, in-
trinsic factors of diseases undergoing neurorehabilitation
should be carefully evaluated when they represent pos-
sible risks for worsening a pre-existing PH or CFP.
Along with pain assessment and treatment, sleep disor-
ders should be evaluated in rehabilitation patients, since
they may be secondary to nocturnal pain presentation
[184]. Diurnal somnolence, lack of concentration, irrit-
ability and memory disturbances due to poor quality
sleep are additional factors that interfere with rehabilita-
tion programs as well as with pain and produce poor
outcome, especially in patients who need cognitive-
behavioural rehabilitation following severe acquired
brain injury.
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To summarize, the final recommendations of the task
force on PHs and other CFPs of the ICCPN are:
1) The modality to be used for diagnosing any of the
above pain conditions is provided by ICHD with a level
of recommendation 1++ and a level of evidence A.
2) For as pharmacological and non-pharmacological
treatment of PHs, therapeutic SISC guidelines
have been accepted as the recommended refer-
ence (1++) with an A level of evidence. Within
this reference, the different recommendation levels
are provided for any treatment. It is noteworthy
that non-pharmacological non-invasive therapies are
beneficial: the next step should be to inform patients
on the wide range of additional treatments to be com-
bined with the common pharmacological treatments.
Non-pharmacological therapies are useful alone or in
combination with preventive pharmacological treat-
ment, although scientific evidences and adequate clin-
ical trials are not sufficient for scoring the most of
them as highly recommended. Non-drug management
should always be considered although the scientific
basis is limited.
3) Invasive procedure to treat pain should be regarded as
a second order choice, due to the inner risk of any
invasive approach. Surgical procedures are not
indicated in most patients with cluster headache
(grade C recommendation). Patients with chronic
intractable headache should be referred to centres with
experience in neuro-invasive procedures, as for any
other pain syndrome seeking for this kind of approach,
and each alternative should be tried before a definitive
procedure is performed (good practice point).
As for PHs and other CFP [2], recommendations of the
ICCPN have been published in several articles in the
October and December 2016 issues of the European
Journal of Physical and Rehabilitation Medicine, except
for psychological assessment and predictive value of
psychological factors in neurorehabilitation patients which
is available on April 2016 issue of Frontiers in Psychology
Journal [96]. All articles are freely accessible on PubMed
and easily found through keyword “ICCPN”. As stated by
the Authors, in the editorial that sums up the ICCPN
whole work “We hope that the conclusions and recom-
mendations of the ICCPN may both offer practical and
useful information on how to deal with pain in patients
undergoing rehabilitation for neurological diseases, and
represent the basis for future high-quality studies on this
topic” [185]. For as PHs and other CFP in neurorehabilita-
tion are concerned, the major issue is the lack of epi-
demiological data and therefore quality studies are needed
to address specific aspects. The availability of multidiscip-
linary interventions in neurorehabilitation setting should
encourage treatment of headaches and other CFP, al-
though independent from the disability that has prompted
the need for rehabilitation, to ease the burden and favour
the outcome of disabled patients. This would also encour-
age clinical research in this field to provide better evi-
dences regarding the utility of non-pharmacological, i.e.
manual and psychological therapy in PHs and other CFPs.
Furthermore and viceversa, rehabilitation programs could
be proposed as such in chronic headaches and other CFPs
refractory to outpatient-based treatments. To conclude,
the use of diagnostic (3, 4) and treatment (20) guidelines
for headache is highly recommended in the rehabilitative
setting for neurological disease other than headaches. In
addition to recommended pharmacological options, man-
ual and psychological therapies should be included within
a multidisciplinary approach for both PHs and other
CFPs, given their widespread availability in neurorehabil-
itative settings and potential or proved efficacy. Surgical
procedures should be proposed in selected conditions only
after the failure of adequate conservative approach.
Specific, high quality studies are encouraged to increase
the evidence and to define appropriate approaches to PHs
and other CFPs in the neurorehabilitation setting.
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techniques; MIDAS: Migraine Disability Assessment Score Questionnaire;
Mind-T: Mindfulness Therapy; MOH: medication overuse headache;
MT: manual therapy; MVD: microvascular decompression;
NSAIDs: nonsteroidal anti-inflammatory drugs; ODA: online digital assistance;
OMT: Osteopathic Manipulative Treatment; ONS: occipital nerve stimulation;
PH: primary headache; PTH: post-traumatic headache; RCT: Randomized
Controlled Trial; RFT: radiofrequency rhizotomy; RT: relaxation training;
SISC: Società Italiana per lo Studio delle Cefalee (Italian Society for the Study of
Headaches); SM: spinal manipulations; SR: systematic reviews; TMD: temporo-
mandibular disorder; TMJ: temporomandibular joints; TN: trigeminal neuralgia;
TTH: tension type headache; VAS: visual analogic scale
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